Together our results most clearly highlighted the importance of TEK, LDB2, ATF6 and UBQLN1 in NSCLC patient BE responses, underscoring the value of examining system-level gene interactions in order to better understand the determinants of lung cancer patient therapeutic responsiveness. This evidence concerns the gene ATF6 and non-small cell lung carcinoma.